The tumor as a dynamic metabolic interaction network: From the Warburg effect to multi-node collapse as a therapeutic strategy
Cancer metabolism research has long been shaped by a pathway-centric paradigm, in which individual biochemical routes—most prominently aerobic glycolysis (the Warburg effect)—are studied and targeted in relative isolation. Accumulating evidence from systems biology, multi-omics profiling, and computational oncology suggests, however, that this view is insufficient to explain the adaptive resilience that solid tumors routinely demonstrate against metabolic inhibitors. Here we propose a conceptual synthesis: the tumor dynamic metabolic interaction network, a graph-theoretic framework in which metabolic enzymes and transporters constitute nodes, substrate fluxes define weighted edges, and the system’s overall state is governed by topological properties such as betweenness centrality and eigenvector centrality. Within this framework, we elaborate the hypothesis of dynamic network collapse (DNC)—the notion that simultaneous perturbation of several high-centrality nodes may push the tumor metabolic network beyond a thermodynamic instability threshold, triggering irreversible functional disintegration that cannot be escaped through known compensatory rerouting. We review the three dominant metabolic axes of tumor survival—glucose (GLUT1/HK2/PKM2), glutamine (SLC1A5/GLS1), and lactate efflux (MCT1/MCT4)—and examine how each contributes to immunosuppression through metabolic competition with cytotoxic T lymphocytes and through the acidification of the tumor microenvironment. We further discuss genome-scale metabolic models, flux balance analysis, and graph neural network approaches that may render the DNC concept computationally actionable. The clinical implications of multi-node targeting are considered alongside the limitations of existing evidence and unresolved methodological challenges. Although the DNC hypothesis remains to be tested experimentally in relevant in vivo models, it provides a coherent rationale for the next generation of combination metabolic therapies and for patient-specific metabolic profiling as a decision tool.
- Vander Heiden MG, Cantley LC, Thompson CB. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science. 2009;324(5930):1029-1033. doi: 10.1126/science.1160809
- Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646-674. doi: 10.1016/j.cell.2011.02.013
- Liberti MV, Locasale JW. The Warburg effect: how does it benefit cancer cells? Trends Biochem Sci. 2016;41(3):211-218. doi: 10.1016/j.tibs.2015.12.001
- DeBerardinis RJ, Chandel NS. Fundamentals of cancer metabolism. Sci Adv. 2016;2(5):e1600200. doi: 10.1126/sciadv.1600200
- Altman BJ, Stine ZE, Dang CV. From Krebs to clinic: glutamine metabolism to cancer therapy. Nat Rev Cancer. 2016;16(10):619-634. doi: 10.1038/nrc.2016.71
- Jeong H, Mason SP, Barabási AL, Oltvai ZN. Lethality and centrality in protein networks. Nature. 2001;411(6833):41-42. doi: 10.1038/35075138
- Barabási AL, Gulbahce N, Loscalzo J. Network medicine: a network-based approach to human disease. Nat Rev Genet. 2011;12(1):56-68. doi: 10.1038/nrg2918
- Lee DS, Park J, Kay KA, et al. The implications of human metabolic network topology for disease comorbidity. Proc Natl Acad Sci USA. 2008;105(29):9880-9885. doi: 10.1073/pnas.0802208105
- Thiele I, Swainston N, Fleming RM, et al. A community-driven global reconstruction of human metabolism. Nat Biotechnol. 2013;31(5):419-425. doi: 10.1038/nbt.2488
- Robinson JL, Kocabaş P, Wang H, et al. An atlas of human metabolism. Sci Signal. 2020;13(624):eaaz1482. doi: 10.1126/scisignal.aaz1482
- Folger O, Jerby L, Frezza C, et al. Predicting selective drug targets in cancer through metabolic networks. Mol Syst Biol. 2011;7:501. doi: 10.1038/msb.2011.35
- Jerby L, Wolf L, Denkert C, et al. Metabolic associations of reduced proliferation and oxidative stress in advanced breast cancer. Cancer Res. 2012;72(22):5712-5720. doi: 10.1158/0008-5472.CAN-12-2215
- Ravasz E, Somera AL, Mongru DA, Oltvai ZN, Barabási AL. Hierarchical organization of modularity in metabolic networks. Science. 2002;297(5586):1551-1555. doi: 10.1126/science.1073374
- Patra KC, Wang Q, Bhaskar PT, et al. Hexokinase 2 is required for tumor initiation and maintenance and its systemic deletion is therapeutic in mouse models of cancer. Cancer Cell. 2013;24(2):213-228. doi: 10.1016/j.ccr.2013.06.014
- Hitosugi T, Kang S, Vander Heiden MG, et al. Tyrosine phosphorylation inhibits PKM2 to promote the Warburg effect and tumor growth. Sci Signal. 2009;2(97):ra73. doi: 10.1126/scisignal.2000431
- DeBerardinis RJ, Mancuso A, Daikhin E, et al. Beyond aerobic glycolysis: transformed cells can engage in glutamine metabolism that exceeds the requirement for protein and nucleotide synthesis. Proc Natl Acad Sci USA. 2007;104(49):19345-19350. doi: 10.1073/pnas.0709747104
- Gao P, Tchernyshyov I, Chang TC, et al. c-Myc suppression of miR-23a/b enhances mitochondrial glutaminase expression and glutamine metabolism. Nature. 2009;458(7239):762-765. doi: 10.1038/nature07823
- Bhutia YD, Babu E, Ramachandran S, Ganapathy V. Amino acid transporters in cancer and their relevance to ‘glutamine addiction’: novel targets for the design of a new class of anticancer drugs. Cancer Res. 2015;75(9):1782-1788. doi: 10.1158/0008-5472.CAN-14-3745
- Momcilovic M, Bailey ST, Lee JT, et al. The GSK3 signaling axis regulates adaptive glutamine metabolism in lung squamous cell carcinoma. Cancer Cell. 2018;33(5):905-921.e5. doi: 10.1016/j.ccell.2018.04.002
- Halestrap AP, Wilson MC. The monocarboxylate transporter family—role and regulation. IUBMB Life. 2012;64(2):109-119. doi: 10.1002/iub.607
- Whitaker-Menezes D, Martinez-Outschoorn UE, Lin Z, et al. Evidence for a stromal-epithelial ‘lactate shuttle’ in human tumors: MCT4 is a marker of oxidative stress in cancer-associated fibroblasts. Cell Cycle. 2011;10(11):1772-1783. doi: 10.4161/cc.10.11.15659
- Brand A, Singer K, Koehl GE, et al. LDHA-associated lactic acid production blunts tumor immunosurveillance by T and NK cells. Cell Metab. 2016;24(5):657-671. doi: 10.1016/j.cmet.2016.08.011
- Certo M, Tsai CH, Pucino V, Ho PC, Mauro C. Lactate modulation of immune responses in inflammatory versus tumour microenvironments. Nat Rev Immunol. 2021;21(3):151-161. doi: 10.1038/s41577-020-0406-2
- Halford SER, Veal GJ, Wedge SR, et al. A phase I dose-escalation study of AZD3965, an oral monocarboxylate transporter 1 inhibitor, in patients with advanced cancer. Clin Cancer Res. 2023;29(8):1429-1439. doi: 10.1158/1078-0432.CCR-22-2263
- Xu Z, Wang X, Cheng H, Li J, Zhang X, Wang X. The role of MCT1 in tumor progression and targeted therapy: a comprehensive review. Front Immunol. 2025;16:1610466. doi: 10.3389/fimmu.2025.1610466
- Benjamin D, Robay D, Hindupur SK, et al. Dual inhibition of the lactate transporters MCT1 and MCT4 is synthetic lethal with metformin due to NAD+ depletion in cancer cells. Cell Rep. 2018;25(11):3047-3058.e4. doi: 10.1016/j.celrep.2018.11.043
- Chang CH, Qiu J, O’Sullivan D, et al. Metabolic competition in the tumor microenvironment is a driver of cancer progression. Cell. 2015;162(6):1229-1241. doi: 10.1016/j.cell.2015.08.016
- Pearce EL, Poffenberger MC, Chang CH, Jones RG. Fueling immunity: insights into metabolism and lymphocyte function. Science. 2013;342(6155):1242454. doi: 10.1126/science.1242454
- Huang Y, Mohanty V, Dede M, et al. Characterizing cancer metabolism from bulk and single-cell RNA-seq data using METAFlux. Nat Commun. 2023;14(1):4883. doi: 10.1038/s41467-023-40457-w
- Ho PC, Bihuniak JD, Macintyre AN, et al. Phosphoenolpyruvate is a metabolic checkpoint of anti-tumor T cell responses. Cell. 2015;162(6):1217-1228. doi: 10.1016/j.cell.2015.08.012
- Lv H, Wu X, Zhang X, et al. Glutamine: a new strategy for targeted metabolic therapy in the tumor microenvironment. Cell Death Discov. 2025;11:459. doi: 10.1038/s41420-025-02767-4
- Pilon-Thomas S, Kodumudi KN, El-Kenawi AE, et al. Neutralization of tumor acidity improves antitumor responses to immunotherapy. Cancer Res. 2016;76(6):1381-1390. doi: 10.1158/0008-5472.CAN-15-1743
- Bola BM, Chadwick AL, Michopoulos F, et al. Inhibition of monocarboxylate transporter-1 (MCT1) by AZD3965 enhances radiosensitivity by reducing lactate transport. Mol Cancer Ther. 2014;13(12):2805-2816. doi: 10.1158/1535-7163.MCT-13-1091
- Cassetta L, Pollard JW. Targeting macrophages: therapeutic approaches in cancer. Nat Rev Drug Discov. 2018;17(12):887-904. doi: 10.1038/nrd.2018.169
- Hangauer MJ, Viswanathan VS, Ryan MJ, et al. Drug-tolerant persister cancer cells are vulnerable to GPX4 inhibition. Nature. 2017;551(7679):247-250. doi: 10.1038/nature24297
- Kaelin WG Jr, McKnight SL. Influence of metabolism on epigenetics and disease. Science. 2013;339(6116):1336-1340. doi: 10.1126/science.1238426
- Sousa CM, Biancur DE, Wang X, et al. Pancreatic stellate cells support tumour metabolism through autophagic alanine secretion. Nature. 2016;536(7617):479-483. doi: 10.1038/nature19084
- Birsoy K, Wang T, Chen WW, Freinkman E, Abu-Remaileh M, Sabatini DM. An essential role of the mitochondrial electron transport chain in cell proliferation is to enable aspartate synthesis. Cell. 2015;162(3):540-551. doi: 10.1016/j.cell.2015.07.016
- Locasale JW, Grassian AR, Melman T, et al. Phosphoglycerate dehydrogenase diverts glycolytic flux and contributes to oncogenesis. Nat Genet. 2011;43(9):869-874. doi: 10.1038/ng.890
- Lewis JE, Forshaw TE, Boothman DA, Furdui CM, Kemp ML. Personalized genome-scale metabolic models identify targets of redox metabolism in radiation-resistant tumors. Cell Syst. 2021;12(1):68-81.e11. doi: 10.1016/j.cels.2020.12.001
- Zielinski DC, Jamshidi N, Corbett AJ, et al. Systems biology analysis of drivers underlying hallmarks of cancer cell metabolism. Sci Rep. 2017;7:41241. doi: 10.1038/srep41241
- Le A, Cooper CR, Gouw AM, et al. Inhibition of lactate dehydrogenase A induces oxidative stress and inhibits tumor progression. Proc Natl Acad Sci USA. 2010;107(5):2037-2042. doi: 10.1073/pnas.0914433107
- Qing G, Li B, Vu A, et al. ATF4 regulates MYC-mediated neuroblastoma cell death upon glutamine deprivation. Cancer Cell. 2012;22(5):631-644. doi: 10.1016/j.ccr.2012.09.021
- Gogoshin G, Rodin AS. Graph neural networks in cancer and oncology research: emerging and future trends. Cancers. 2023;15(24):5858. doi: 10.3390/cancers15245858
- Liu M, Srivastava G, Ramanujam J, Brylinski M. SynerGNet: a graph neural network model to predict anticancer drug synergy. Biomolecules. 2024;14(3):253. doi: 10.3390/biom14030253
- Sullivan MR, Danai LV, Lewis CA, et al. Quantification of microenvironmental metabolites in murine cancers reveals determinants of tumor nutrient availability. eLife. 2019;8:e44235. doi: 10.7554/eLife.44235
- Tanıl E, Nikerel E. Multi-omic data integration and exploiting metabolic models using systems biology approach increase precision in subtyping and early diagnosis of cancer. Quant Biol. 2025;13(4):e70012. doi: 10.1002/qub2.70012
- Gopalakrishnan V, Spencer CN, Nezi L, et al. Gut microbiome modulates response to anti–PD-1 immunotherapy in melanoma patients. Science. 2018;359(6371):97-103. doi: 10.1126/science.aan4236
